Abstract
Background
Wolfram Syndrome is a very rare genetic disease causing diabetes mellitus, blindness, deafness, diabetes insipidus, and progressive brainstem degeneration. Neurologic symptoms of affected patients include ataxia, sleep apnea, loss of bladder control, dysphagia, loss of taste, and accompanying psychiatric symptoms as a sign of progressive neurodegeneration. Its genetic cause is mainly biallelic mutations of the Wolframin endoplasmatic reticulum transmembrane glycoprotein gene Wfs1. These result in increased ER stress, which in turn induces apoptosis and leads to the depletion of the corresponding cells and a loss of their physiological functions. Though diabetes mellitus is mostly treated by insulin, there is still no proven cure for the disease in general. It leads to premature death in affected individuals—usually within the 4th decade of live.
Current research and treatment trials
Clinical studies are currently being conducted at various locations worldwide to test a therapy for the disease using various approaches.
Potentail of virtual netowrking
As rare diseases in general represent a major challenge for individual clinicians and researchers due to the rarity of diagnosis, the lack of evidence and of value of existing research, international cooperation, coordination and networking leading to an alignment of different stakeholders is necessary to support patients and increase knowledge about these diseases, like wolfram syndrome.
Conclusion
ENDO-ERN and EURRECA are two EU-funded networks that aim to promote knowledge sharing, education and research on rare endocrine diseases.
Similar content being viewed by others
References
L. Rigoli, F. Lombardo, C. Di Bella, Wolfram syndrome and WFS1 gene. Clin. Genet. 79(2 Feb), 103–17 (2011). https://doi.org/10.1111/j.1399-0004.2010.01522.x. Epub 2010 Aug 26
F. Dingreville, B. Panthu, C. Thivolet, S. Ducreux, Y. Gouriou, S. Pesenti, M.A. Chauvin, K. Chikh, E. Errazuriz-Cerda, F. Van Coppenolle, J. Rieusset, A.M. Madec, Differential Effect of Glucose on ER-Mitochondria Ca2+ Exchange Participates in Insulin Secretion and Glucotoxicity-Mediated Dysfunction of β-Cells. Diabetes 68(9 Sep), 1778–1794 (2019). https://doi.org/10.2337/db18-1112. Epub 2019 Jun 7
W.S. Lee, W.H. Yoo, H.J. Chae, ER Stress and Autophagy. Curr. Mol. Med. 15(8), 735–45 (2015). https://doi.org/10.2174/1566524015666150921105453
D. Ariyasu, H. Yoshida, Y. Hasegawa, Endoplasmic reticulum (ER) stress and endocrine disorders. Int J. Mol. Sci. 18(2), 382 (2017). https://doi.org/10.3390/ijms18020382
T. Yamada, H. Ishihara, A. Tamura, R. Takahashi, S. Yamaguchi, D. Takei, A. Tokita, C. Satake, F. Tashiro, H. Katagiri, H. Aburatani, J. Miyazaki, Y. Oka, WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. Hum. Mol. Genet. 15(10 May), 1600–9 (2006). https://doi.org/10.1093/hmg/ddl081. Epub 2006 Mar 28
E. Domenech, M. Gomez-Zaera, V. Nunes, Wolfram/DIDMOAD syndrome, a heterogenic and molecularly complex neurodegenerative disease. Pediatr. Endocrinol. Rev. 3(3 Mar), 249–57 (2006)
L. Rigoli, C. Aloi, A. Salina, C. Di Bella, G. Salzano, R. Caruso, E. Mazzon, M. Maghnie, G. Patti, G. D’Annunzio, F. Lombardo, Wolfram syndrome 1 in the Italian population: genotype-phenotype correlations. Pediatr. Res. 87(3 Feb), 456–462 (2020). https://doi.org/10.1038/s41390-019-0487-4. Epub 2019 Jul 2
J. Rohayem, C. Ehlers, B. Wiedemann, R. Holl, K. Oexle, O. Kordonouri, G. Salzano, T. Meissner, W. Burger, E. Schober, A. Huebner, M.A. Lee-Kirsch; Wolfram Syndrome Diabetes Writing Group, Diabetes and neurodegeneration in Wolfram syndrome: a multicenter study of phenotype and genotype. Diabetes Care 34(7 Jul), 1503–10 (2011). https://doi.org/10.2337/dc10-1937. Epub 2011 May 20
K. Takeda, H. Inoue, Y. Tanizawa et al. WFS1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum. Mol. Genet. 10, 477–484 (2001)
H. Luuk, S. Koks, M. Plaas, J. Hannibal, J.F. Rehfeld, E. Vasar, Distribution of Wfs1 protein in the central nervous system of the mouse and its relation to clinical symptoms of the Wolfram syndrome. J. Comp. Neurol. 509(6 Aug), 642–60 (2008). https://doi.org/10.1002/cne.21777.
K. Ueda, J. Kawano, K. Takeda, T. Yujiri, K. Tanabe, T. Anno, M. Akiyama, J. Nozaki, T. Yoshinaga, A. Koizumi, K. Shinoda, Y. Oka, Y. Tanizawa, Endoplasmic reticulum stress induces Wfs1 gene expression in pancreatic beta-cells via transcriptional activation. Eur. J. Endocrinol. 153(1 Jul), 167–76 (2005). https://doi.org/10.1530/eje.1.01945
S.G. Fonseca, S. Ishigaki, C.M. Oslowski et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J. Clin. Investig. 120, 744–755 (2010)
F. Urano, Wolfram Syndrome: diagnosis, Management, and Treatment. Curr. Diab. Rep. 16(1 Jan), 6 (2016). https://doi.org/10.1007/s11892-015-0702-6
M.L. de Heredia, R. Cleries, V. Nunes, Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype. Genet. Med. 15(7), 497–506 (2013). https://doi.org/10.1038/gim.2012.180
D. Abreu, F. Urano, Current Landscape of Treatments for Wolfram Syndrome. Trends Pharm. Sci. 40(10 Oct), 711–714 (2019). https://doi.org/10.1016/j.tips.2019.07.011. Epub 2019 Aug 13
T.G. Barrett, S.E. Bundey, A.F. Macleod, Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 346(8988 Dec), 1458–63 (1995). https://doi.org/10.1016/s0140-6736(95)92473-6
L. Rigoli, P. Bramanti, C. Di Bella, F. De Luca, Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr. Res. 83 (5 May), 921–929 (2018). https://doi.org/10.1038/pr.2018.17. Epub 2018 Feb 28. Erratum in: Pediatr Res. 2018 Nov;84(5):787
L. Hansen, H. Eiberg, T. Barrett, T. Bek, P. Kjaersgaard, L. Tranebjaerg et al. Mutation analysis of the WFS1 gene in seven Danish Wolfram syndrome families; four new mutations identified. Eur. J. Hum. Genet. 13(12), 1275–1284 (2005). https://doi.org/10.1038/sj.ejhg.5201491
S. Kumar, Wolfram syndrome: important implications for pediatricians and pediatric endocrinologists. Pediatr. Diabetes 11(1), 28–37 (2010 Feb). https://doi.org/10.1111/j.1399-5448.2009.00518.x. Epub 2009 Dec 14
R.K. Karzon, T.E. Hullar, Audiologic and vestibular findings in Wolfram syndrome. Ear Hear. 34(6), 809–12 (2013). https://doi.org/10.1097/AUD.0b013e3182944db7
A. Chaussenot, S. Bannwarth, C. Rouzier, B. Vialettes, S.A. Mkadem, B. Chabrol, A. Cano, P. Labauge, V. Paquis-Flucklinger, Neurologic features and genotype-phenotype correlation in Wolfram syndrome. Ann. Neurol. 69(3 Mar), 501–8 (2011). https://doi.org/10.1002/ana.22160. Epub 2010 Dec 28
S. Lu, K. Kanekura, T. Hara, J. Mahadevan, L. D. Spears, C. M. Oslowski, R. Martinez, M. Yamazaki-Inoue, M. Toyoda, A. Neilson, P. Blanner, C. M. Brown, C. F. Semenkovich, B. A. Marshall, T. Hershey, A. Umezawa, P. A. Greer, & F. Urano, A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. Proceed. Natl Acad. Sci. USA, 111(49), E5292–E5301 (2014). https://doi.org/10.1073/pnas.1421055111
L. Shang, H. Hua, K. Foo, H. Martinez, K. Watanabe, M. Zimmer, D.J. Kahler, M. Freeby, W. Chung, C. LeDuc, R. Goland, R.L. Leibel, D. Egli, β-cell dysfunction due to increased ER stress in a stem cell model of Wolfram syndrome. Diabetes 63(3 Mar), 923–33 (2014). https://doi.org/10.2337/db13-0717. Epub 2013 Nov 13
A. Terasmaa, U. Soomets, J. Oflijan, M. Punapart, M. Hansen, V. Matto, K. Ehrlich, A. Must, S. Kõks, E. Vasar, Wfs1 mutation makes mice sensitive to insulin-like effect of acute valproic acid and resistant to streptozocin. J. Physiol. Biochem. 67(3 Sep), 381–90 (2011). https://doi.org/10.1007/s13105-011-0088-0. Epub 2011 Apr 2
Z. Li, F. Wu, X. Zhang, Y. Chai, D. Chen, Y. Yang, K. Xu, J. Yin, R. Li, H. Shi, Z. Wang, X. Li, J. Xiao, H. Zhang, Valproate Attenuates Endoplasmic Reticulum Stress-Induced Apoptosis in SH-SY5Y Cells via the AKT/GSK3β Signaling Pathway. Int J. Mol. Sci. 18(2 Feb), 315 (2017). https://doi.org/10.3390/ijms18020315
C. Kakiuchi, S. Ishigaki, C.M. Oslowski, S.G. Urano, T. Kato, F. Urano, Valproate, a mood stabilizer, induces WFS1 expression and modulates its interaction with ER stress protein GRP94. PLoS ONE 4(1), e4134 (2009). https://doi.org/10.1371/journal.pone.0004134. Epub 2009 Jan 6
K. Batjargal, T. Tajima, E.F. Jimbo, T. Yamagata, Effect of 4-phenylbutyrate and valproate on dominant mutations of WFS1 gene in Wolfram syndrome. J. Endocrinol. Investig. 43(9 Sep), 1317–1325 (2020). https://doi.org/10.1007/s40618-020-01228-2. Epub 2020 Mar 26
M. Kondo, K. Tanabe, K. Amo-Shiinoki, M. Hatanaka, T. Morii, H. Takahashi, S. Seino, Y. Yamada, Y. Tanizawa, Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome. Diabetologia 61(10 Oct), 2189–2201 (2018). https://doi.org/10.1007/s00125-018-4679-y. Epub 2018 Jul 28
K. Seppa, M. Toots, R. Reimets, T. Jagomäe, T. Koppel, M. Pallase, S. Hasselholt, M. Krogsbæk Mikkelsen, J. Randel Nyengaard, E. Vasar, A. Terasmaa, M. Plaas, GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome. Sci. Rep. 9(1 Oct), 15742 (2019). https://doi.org/10.1038/s41598-019-52295-2
M. Toots, K. Seppa, T. Jagomäe, T. Koppel, M. Pallase, I. Heinla, A. Terasmaa, M. Plaas, E. Vasar, Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome. Sci. Rep. 8(1 Jul), 10183 (2018). https://doi.org/10.1038/s41598-018-28314-z
K.G. Maxwell, P. Augsornworawat, L. Velazco-Cruz, M.H. Kim, R. Asada, N.J. Hogrebe, S. Morikawa, F. Urano, J.R. Millman, Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice. Sci. Transl. Med. 12(540 Apr), eaax9106 (2020). https://doi.org/10.1126/scitranslmed.aax9106
S. Blöß, C. Klemann, A.K. Rother, S. Mehmecke, U. Schumacher, U. Mücke et al. Diagnostic needs for rare diseases and shared prediagnostic phenomena: results of a German-wide expert Delphi survey. PLoS ONE 12(2), e0172532 (2017)
K.R. Bogart, V.L. Irvin, Health-related quality of life among adults with diverse rare disorders. Orphanet. J. Rare Dis. 12(1), 177 (2017)
M. Pai, C.H.T. Yeung, E.A. Akl, A. Darzi, C. Hillis, K. Legault, J.J. Meerpohl, N. Santesso, D. Taruscio, M. Verhovsek, H.J. Schünemann, A. Iorio, Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. BMC Med. Res. Methodol. 19(1 Mar), 67 (2019). https://doi.org/10.1186/s12874-019-0713-0
D. Julkowska, C.P. Austin, C.M. Cutillo, D. Gancberg, C. Hager, J. Halftermeyer, A.H. Jonker, L.P.L. Lau, I. Norstedt, A. Rath, R. Schuster, E. Simelyte, S. van Weely, The importance of international collaboration for rare diseases research: a European perspective. Gene. Ther. 24(9 Sep), 562–571 (2017). https://doi.org/10.1038/gt.2017.29. Epub 2017 Jul 27
Y. Kodra, J. Weinbach, M. Posada-de-la-Paz, A. Coi, S.L. Lemonnier, D. van Enckevort, M. Roos, A. Jacobsen, R. Cornet, S.F. Ahmed, V. Bros-Facer, V. Popa, M. Van Meel, D. Renault, R. von Gizycki, M. Santoro, P. Landais, P. Torreri, C. Carta, D. Mascalzoni, S. Gainotti, E. Lopez, A. Ambrosini, H. Müller, R. Reis, F. Bianchi, Y.R. Rubinstein, H. Lochmüller, D. Taruscio, Recommendations for Improving the Quality of Rare Disease Registries. Int J. Environ. Res. Public Health 15(8 Aug), 1644 (2018). https://doi.org/10.3390/ijerph15081644
E. Vermeulen, K. Karsenberg, J.H. van der Lee, S.N. de Wildt, Involve Children and Parents in Clinical Studies. Clin. Transl. Sci. 13(1 Jan), 11–13 (2020). https://doi.org/10.1111/cts.12696. Published online 2019 Oct 24
T. Eggermann, M. Elbracht, I. Kurth, A. Juul, T.H. Johannsen, I. Netchine, G. Mastorakos, G. Johannsson, T.J. Musholt, M. Zenker, D. Prawitt, A.M. Pereira, O. Hiort, European Reference Network on Rare Endocrine Conditions (ENDO-ERN. Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN).Orphanet J. Rare Dis. 15(1 Jun), 144 (2020). https://doi.org/10.1186/s13023-020-01420-w.
O. Hiort, M. Cools, A. Springer, K. McElreavey, A. Greenfield, S.A. Wudy, A. Kulle, S.F. Ahmed, A. Dessens, A. Balsamo, M. Maghnie, M. Bonomi, M. Dattani, L. Persani, L. Audi, COST Actions DSDnet and GnRH Network as well as the European Reference Network for Rare Endocrine Conditions (Endo–ERN). Addressing gaps in care of people with conditions affecting sex development and maturation. Nat. Rev. Endocrinol. 15(10 Oct), 615–622 (2019). https://doi.org/10.1038/s41574-019-0238-y. Epub 2019 Aug 12
F. de Vries, M. Bruin, A. Cersosimo, C.N. van Beuzekom, S.F. Ahmed, R.P. Peeters, N.R. Biermasz, O. Hiort, A.M. Pereira, An overview of clinical activities in Endo-ERN: the need for alignment of future network criteria. Eur. J. Endocrinol. 183(2 Aug), 141–148 (2020). https://doi.org/10.1530/EJE-20-0197
C. Sangaleti, M.C. Schveitzer, M. Peduzzi, Zoboli ELCP, Soares CB. Experiences and shared meaning of teamwork and interprofessional collaboration among health care professionals in primary health care settings: a systematic review. JBI Database Syst. Rev. Implement Rep. 15(11 Nov), 2723–2788 (2017). https://doi.org/10.11124/JBISRIR-2016-003016
S.R. Ali, J. Bryce, M. Cools, M. Korbonits, J.G. Beun, D. Taruscio, T. Danne, M. Dattani, O.M. Dekkers, A. Linglart, I. Netchine, A. Nordenstrom, A. Patocs, L. Persani, N. Reisch, A. Smyth, Z. Sumnik, W.E. Visser, O. Hiort, A.M. Pereira, S.F. Ahmed, The current landscape of European registries for rare endocrine conditions. Eur. J. Endocrinol. 180(1 Jan), 89–98 (2019). https://doi.org/10.1530/EJE-18-0861.
S.R. Ali, J. Bryce, M. Cools, T. Danne, M.T. Dattani, O.M. Dekkers, O. Hiort, A. Linglart, I. Netchine, A. Nordenstrom, A. Patocs, A.M. Pereira, L. Persani, N. Reisch, A. Smyth, Z. Sumnik, D. Taruscio, W.E. Visser, S.F. Ahmed, SUN-070 European Registries for Rare Endocrine Conditions (EuRRECa): Results from the Platform for E-reporting of Rare Endocrine Conditions (e-REC). J. Endocr. Soc. 4(Suppl 1 May), SUN-070 (2020). https://doi.org/10.1210/jendso/bvaa046.127. Published online 2020 May 8
D. Pacaud, A. Schwandt, C. de, Beaufort, K. Casteels, J. Beltrand, N.H. Birkebaek, M. Campagnoli, N. Bratina, C. Limbert, S. O’Riordan, R. Ribeiro, A. Gerasimidi-Vazeou, L. Petruzelkova, R. Verkauskiene, I.D. Krisane; the SWEET Study Group, A description of clinician reported diagnosis of type 2 diabetes and other non-type 1 diabetes included in a large international multicentered pediatric diabetes registry. SWEET Pediatr. Diabetes 17(Suppl. 23), 24–31 (2016)
P. Marchetti, A.M. Schulte, L. Marselli, E. Schoniger, M. Bugliani, W. Kramer, L. Overbergh, S. Ullrich, A.L. Gloyn, M. Ibberson, G. Rutter, P. Froguel, L. Groop, M.I. McCarthy, F. Dotta, R. Scharfmann, C. Magnan, D.E. Eizirik, C. Mathieu, M. Cnop, B. Thorens, M. Solimena, Fostering improved human islet research: a European perspective. Diabetologia 62(8), 1514–1516 (2019). https://doi.org/10.1007/s00125-019-4911-4. Published online 2019 Jun 13
C.P. Austin, C.M. Cutillo, L.P.L. Lau, A.H. Jonker, A. Rath, D. Julkowska, D. Thomson, S.F. Terry, B. de Montleau, D. Ardigò, V. Hivert, K.M. Boycott, G. Baynam, P. Kaufmann, D. Taruscio, H. Lochmüller, M. Suematsu, C. Incerti, R. Draghia-Akli, I. Norstedt, L. Wang, H.J.S. Dawkins, International Rare Diseases Research Consortium (IRDiRC). Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Clin. Transl. Sci. 11(1 Jan), 21–27 (2018). https://doi.org/10.1111/cts.12500
H.J.S. Dawkins, R. Draghia-Akli, P. Lasko, L.P.L. Lau, A.H. Jonker, C.M. Cutillo, A. Rath, K.M. Boycott, G. Baynam, H. Lochmüller, P. Kaufmann, Y. Le Cam, V. Hivert, C.P. Austin, International Rare Diseases Research Consortium (IRDiRC). Progress in Rare Diseases Research 2010-2016: An IRDiRC Perspective. Clin. Transl. Sci. 11(1), 11–20 (2018). https://doi.org/10.1111/cts.12501. Epub 2017 Oct 23
Acknowledgements
The authors would also like to thank the European Society of Endocrinology, the International Society for Pediatric and Adolescent Diabetes and the European Society for Pediatric Endocrinology for their generous support.
Funding
This paper is based on work performed with the support of non-profit organizations and public bodies for funding of scientific research conducted within the European Union: Innovative Medicines Initiative Joint Undertaking under grant agreement 115797 (INNODIA), which include financial contributions from European Union’s Seventh Framework Programme (FP7/2007-2013) and Horizon 2020 research and innovation programme, EFPIA, JDRF, the Leona M. and Harry B. Helmsley Charitable Trust, the C4C initiative receiving funding from from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389 supported by the European Union’s Horizon 2020 research and innovation programme and EFPIA, and the project ‘777215/ EuRRECa’ which has funding from the European Union’s Health Programme (2014–2020). SWEET is a registered non-profit charity in Hannover, Germany. It is financed through membership fees of the participating centers (based on income of country of residence according to the World Bank) and corporate members (for the current list see www.sweet-project.org).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Reschke, F., Rohayem, J., Maffei, P. et al. Collaboration for rare diabetes: understanding new treatment options for Wolfram syndrome. Endocrine 71, 626–633 (2021). https://doi.org/10.1007/s12020-021-02622-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-021-02622-3